Log in
CNSX:ATT

Abattis Bioceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.42 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-3360881
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive ATT News and Ratings via Email

Sign-up to receive the latest news and ratings for ATT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abattis Bioceuticals (CNSX:ATT) Frequently Asked Questions

What stocks does MarketBeat like better than Abattis Bioceuticals?

Wall Street analysts have given Abattis Bioceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abattis Bioceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Abattis Bioceuticals' key competitors?

What other stocks do shareholders of Abattis Bioceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abattis Bioceuticals investors own include Aphria Inc. (APHA.TO) (APHA), Surna (SRNA), CannTrust (CTST), HEXO (HEXO), Canopy Growth (WEED), Aurora Cannabis (ACBFF), Aurora Cannabis Inc. (ACB.TO) (ACB), Laird PLC (LRD.L) (LRD), MedReleaf Corp. (LEAF.TO) (LEAF) and Hays plc (HAS.L) (HAS).

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the following people:
  • Robert Abenante CPA, President, Chief Executive Officer, Director (Age 33)
  • David Whitney, Chief Financial Officer
  • Rene David, Chief Operating Officer, Director
  • Christopher P. Cherry, Corporate Controller (Age 40)
  • Hugh Oswald, IR Contact Officer
  • Christina Boddy, Corporate Secretary
  • Peter Gordon, Director
  • James Irving, Director
  • Shuang Xie, Director
  • Guy P. Dancosse QC, Independent Director

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the CNSX under the ticker symbol "ATT."

What is Abattis Bioceuticals' official website?

The official website for Abattis Bioceuticals is www.abattis.com.

How can I contact Abattis Bioceuticals?

Abattis Bioceuticals' mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company can be reached via phone at +1-604-3360881.

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.